Tissue advanced glycation end products are associated with diastolic function and aerobic exercise capacity in diabetic heart failure patients

被引:59
|
作者
Willemsen, Suzan [1 ]
Hartog, Jasper W. L. [1 ]
Hummel, Yoran M. [1 ]
van Ruijven, Marieke H. I. [1 ]
van der Horst, Iwan C. C. [1 ]
van Veldhuisen, Dirk J. [1 ]
Voors, Adriaan A. [1 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, NL-9700 RB Groningen, Netherlands
关键词
Heart failure; Diastolic function; Diabetes; Advanced glycation end products; VENTRICULAR EJECTION FRACTION; RISK-FACTORS; CONSEQUENCES; MELLITUS; STRESS;
D O I
10.1093/eurjhf/hfq168
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims Advanced glycation end products (AGEs) are increased in patients with diabetes and are associated with diastolic dysfunction through the formation of collagen crosslinks in the heart. The association among AGEs, diastolic function, and aerobic capacity in heart failure (HF) patients with and without diabetes is, however, unknown. We therefore studied the association among tissue AGEs, diastolic function, and aerobic capacity in patients with HF with or without diabetes. Methods and results In chronic HF patients (with and without left ventricular systolic dysfunction), tissue AGEs [skin autofluorescence (AF)], diastolic function (echocardiographic mean E' and E/E'), and aerobic capacity [peak oxygen uptake (VO2) on cardiopulmonary exercise testing] were obtained. A total of 49 diabetics and 156 non-diabetics were included. Diabetics were older and had more cardiovascular risk factors, but left ventricular ejection fractions (LVEF) were similar. Tissue AGEs were higher in diabetics compared with non-diabetics (2.8 +/- 0.8 vs. 2.3 +/- 0.7 a.u.; P < 0.001). Furthermore, there was a correlation between tissue AGEs and mean E' (r = -0.30; P < 0.001, after adjustment for age, r = -0.21; P = 0.004). Aerobic capacity was significantly lower in diabetic patients with HF (peak VO2: 17.4 +/- 5.1 vs. 21.7 +/- 6.1 mL/min/kg; P = 0.001), even after adjustment for age and LVEF. Peak VO2 was related to skin AF (P = 0.03), independent of age, diabetes, LVEF, and New York Heart Association functional class. Conclusion Patients with diabetes and HF have similar LVEF but poorer exercise capacity compared with non-diabetic HF patients. Our data suggest that these findings might be explained by the observed association among tissue AGE levels, diastolic function, and exercise capacity.
引用
收藏
页码:76 / 82
页数:7
相关论文
共 50 条
  • [31] Advanced glycation end products (AGE) in the pathogenesis of ischaemic cardiomyopathy in diabetic patients - preliminary report
    Nozynski, Jerzy K.
    Zakliczynski, Michal
    Konecka-Mrowka, Dominika
    Nikiel, Barbara
    Mlynarczyk-Liszka, Joanna
    Lange, Dariusz
    Maruszewski, Marcin
    Zembala, Marian
    KARDIOCHIRURGIA I TORAKOCHIRURGIA POLSKA, 2008, 5 (01): : 56 - 63
  • [32] Coronary flow reserve as a link between diastolic and systolic function and exercise capacity in heart failure
    Snoer, Martin
    Monk-Hansen, Tea
    Olsen, Rasmus Huan
    Pedersen, Lene Roerholm
    Nielsen, Olav Wendelboe
    Rasmusen, Hanne
    Dela, Flemming
    Prescott, Eva
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING, 2013, 14 (07) : 677 - 683
  • [33] Advanced Glycation End Products Promote Heart Failure Through Inducing the Immune Maturation of Dendritic Cells
    Cao, Weiwei
    Chen, Jianwen
    Chen, Yanfang
    Chen, Xi
    Liu, Peiqing
    APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 2014, 172 (08) : 4062 - 4077
  • [34] Clinical and prognostic value of advanced glycation end-products in chronic heart failure
    Hartog, Jasper W. L.
    Voors, Adriaan A.
    Schalkwijk, Casper G.
    Scheijen, Jean
    Smilde, Tom D. J.
    Damman, Kevin
    Bakker, Stephan J. L.
    Smit, Andries J.
    van Veldhuisen, Dirk J.
    EUROPEAN HEART JOURNAL, 2007, 28 (23) : 2879 - 2885
  • [35] Soluble receptor for advanced glycation end products (RAGE) is a prognostic factor for heart failure
    Koyama, Yo
    Takeishi, Yasuchika
    Niizeki, Takeshi
    Suzuki, Satoshi
    Kitahara, Tatsuro
    Sasaki, Toshiki
    Kubota, Isao
    JOURNAL OF CARDIAC FAILURE, 2008, 14 (02) : 133 - 139
  • [36] Advanced Glycation End Products Promote Heart Failure Through Inducing the Immune Maturation of Dendritic Cells
    Weiwei Cao
    Jianwen Chen
    Yanfang Chen
    Xi Chen
    Peiqing Liu
    Applied Biochemistry and Biotechnology, 2014, 172 : 4062 - 4077
  • [37] Exercise Capacity, Peripheral Muscle Strength, and Inactivity in Diabetic Patients With Heart Failure
    Bosnak-Guclu, Meral
    Savci, Sema
    Inal-Ince, Deniz
    Arikan, Hulya
    Tulumen, Erol
    Aytemir, Kudret
    Tokgozoglu, Lale
    TOPICS IN GERIATRIC REHABILITATION, 2012, 28 (01) : 54 - 59
  • [38] Soluble receptor for advanced glycation end products in patients with decreased renal function
    Kalousová, M
    Hodková, M
    Kazderová, M
    Fialová, J
    Tesar, V
    Dusilová-Sulková, S
    Zima, T
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2006, 47 (03) : 406 - 411
  • [39] The role of advanced glycation end products in fracture risk assessment in postmenopausal type 2 diabetic patients
    Gao, Liu
    Liu, Chang
    Hu, Pan
    Wang, Na
    Bao, Xiaoxue
    Wang, Bin
    Wang, Ke
    Li, Yukun
    Xue, Peng
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [40] Predictive value of advanced glycation end products for the development of post-infarction heart failure: a preliminary report
    Raposeiras-Roubin, Sergio
    Rodino-Janeiro, Bruno K.
    Paradela-Dobarro, Beatriz
    Grigorian-Shamagian, Lilian
    Garcia-Acuna, Jose M.
    Aguiar-Souto, Pablo
    Jacquet-Hervet, Michel
    Reino-Maceiras, Mara V.
    Alvarez, Ezequiel
    Gonzalez-Juanatey, Jose R.
    CARDIOVASCULAR DIABETOLOGY, 2012, 11